Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-216791
Filing Date
2026-05-11
Accepted
2026-05-11 16:13:50
Documents
65
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eikn-20260331.htm   iXBRL 10-Q 2577905
2 EX-31.1 eikn-ex31_1.htm EX-31.1 17618
3 EX-31.2 eikn-ex31_2.htm EX-31.2 17574
4 EX-32.1 eikn-ex32_1.htm EX-32.1 10545
5 EX-32.2 eikn-ex32_2.htm EX-32.2 10278
6 GRAPHIC img119830300_0.jpg GRAPHIC 996985
  Complete submission text file 0001193125-26-216791.txt   11333839

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eikn-20260331.xsd EX-101.SCH 1075722
69 EXTRACTED XBRL INSTANCE DOCUMENT eikn-20260331_htm.xml XML 1461488
Mailing Address 230 HARRIET TUBMAN WAY MILLBRAE CA 94030
Business Address 230 HARRIET TUBMAN WAY MILLBRAE CA 94030 341-777-0566
Eikon Therapeutics, Inc. (Filer) CIK: 0001861123 (see all company filings)

EIN.: 842807586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43085 | Film No.: 26963357
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)